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Medulloblastoma, a malignant invasive tumor of the cerebellum, is one of the most common neoplasms of the nervous
system in children. Utilization of the human neurotropic virus JC virus (JCV) early gene T-antigen allowed the development
of a transgenic animal that models human medulloblastoma. Here we describe the characterization of two distinct
populations of cells derived from the JCV-induced mouse medulloblastoma. Results from immunohistochemical and bio-
chemical studies revealed the expression of T-antigen in some but not all tumor cells. In T-antigen-producing cells, T-antigen
was found in association with wild-type p53 and pRb, two tumor suppressors that control cell growth and differentiation. In
cells that lack expression of T-antigen, a novel mutant p53 with a deletion between residues 35 and 123 was detected.
Morphological differences were observed between the two populations of cells, though there was no significant difference
in their growth rates. However, subcutaneous transplantation of the T-antigen-positive, but not T-antigen-negative, cells
resulted in the development of massive tumors in experimental animals. In light of earlier reports on the association of JCV
with human medulloblastoma, the mouse cell lines described in this study may provide a valuable tool for deciphering the
pathways involved in the formation and progression of medulloblastoma. © 2000 Academic Press
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aINTRODUCTION
The oncogenic potential of several viruses, including
polyomaviruses, has been well documented in a variety
of animals, and it has been speculated that some malig-
nancies in humans may be induced by these viruses. In
recent years, the relationship of Simian virus 40 (SV40) to
human cancer has become a focus of attention as re-
sults from a number of studies have led to the detection
of viral sequences in several human tumors, including
ependymomas, choroid plexus papillomas, osteosarco-
mas, and mesotheliomas (Bergsagel et al., 1992; Car-
bone et al., 1996; Lednicky et al., 1995; Testa et al., 1998).
C virus (JCV) is another member of the polyomavirus
amily that has recently received much attention with
egard to its possible association with certain brain tu-
ors (Gallia et al., 1998; Khalili et al., 1999a). JCV is a
uman neurotropic virus infecting greater than 70% of the
uman population and is considered the etiologic agent
f the fatal demyelinating disease of the central nervous
ystem progressive multifocal leukoencephalopathy
PML) (for review see Berger and Concha, 1995). The
tructural organization of the JCV genome isolated from
he brains of PML patients shows substantial similarity to
he SV40 genome, particularly within the region of the
irus that is responsible for expression of the viral early
rotein T-antigen (Frisque et al., 1984). The striking ho-
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65ology between SV40 T-antigen, which possesses trans-
orming ability (Cole, 1996), and JCV T-antigen suggests
hat the JCV early gene product may also have oncogenic
otential. In support of this notion, earlier results from
everal laboratories have clearly established the ability
f JCV to induce malignancies in several animal models
London et al., 1978, 1983; Ohsumi et al., 1985; ZuRhein,
983). Perhaps the most direct evidence for the involve-
ent of JCV T-antigen in tumor formation is presented by
ransgenic animal studies using the JCV early genome
Franks et al., 1996; Small et al., 1986). From these stud-
es it was evident that expression of JCV T-antigen in a
hole animal system can result in the appearance of
rimitive neuroectodermal tumors and adrenal neuro-
lastomas. More recently, we have developed transgenic
ice containing the early genome of the archetype form
f the virus, JCVCY. Mice between the ages of 9 and 13
onths that contain the transgene exhibited signs of
eurological illness and developed cerebellar neuroec-
odermal origin tumors that histologically resembled hu-
an medulloblastoma (Krynska et al., 1999a). This was
n important observation in light of subsequent studies
hat illustrated the presence of JCV DNA sequences in a
ignificant number of human medulloblastomas (Khalili
t al., 1999b; Krynska et al., 1999b). Interestingly, immu-
ohistochemical studies of human tumor tissue have
hown the expression of JCV T-antigen in some, but not
ll, of the tumor cells containing the JCV sequence. This
bservation is reminiscent of JCV-induced medulloblas-
omas in transgenic mice in which not all tumor cells
0042-6822/00 $35.00
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66 KRYNSKA ET AL.were positive for T-antigen production. Here we have
derived T-antigen-positive and T-antigen-negative cell
lines from a mouse medulloblastoma for biological and
molecular studies. Our results show that T-antigen-pro-
ducing cells are morphologically distinct from T-antigen-
negative cells and that T-antigen can be found in asso-
ciation with wild-type p53 and pRb, two tumor suppres-
sors that control cell growth and proliferation. Finally, in
T-antigen-negative cells, we identified the presence of a
novel mutant p53 with a deletion between residues 35
and 123.
RESULTS
A JCV T-antigen transgenic mouse harboring tumors
that resembled human medulloblastomas was sacrificed
and the region of the cerebellum containing the tumor
was dissected for in vitro cell culturing. Tumor tissue was
mechanically dissociated and a mixed cell culture was
prepared. By limiting dilution, four clonal cell lines
FIG. 1. Morphological appearance of clonal cell lines derived from a m
that exhibited similar morphological features, including a moderate d
derived. Four additional cell lines, BS-1B7, BS-1B8, BS-1B13, and BS-1
scant cytoplasm and shorter processes (E through H).(named BS-1a, BS-1b, BS-1c, and BS-1f) were estab-
lished. The four clones exhibited similar microscopicfeatures, which included a moderate degree of cyto-
plasm and a process-bearing morphology (Figs. 1A–1D).
Four additional clonal cell lines, BS-1B7, BS-1B8, BS-
1B13, and BS-1B14, with morphological features distinct
from those of the initial clones, were isolated and were
characterized by scant cytoplasm and shorter processes
(Figs. 1E–1H).
Immunohistochemical evaluation of BS-1B7, BS-1B8,
BS-1B13, and BS-1B14 revealed strong positive nuclear
staining with antibody recognizing JCV T-antigen, while
the other four cell lines, BS-1a, BS-1b, BS-1c, and BS-1f,
showed no evidence of T-antigen expression. Figure 2
illustrates representative data showing that T-antigen
expression was absent in BS-1a (Fig. 2A) and was de-
tected in the nuclei of BS-1B7 (Fig. 2E). Both T-negative
and T-positive cells expressed neuronal nuclear pro-
teins, including neurofilament (Figs. 2B and 2F) and syn-
aptophysin (Figs. 2C and 2G). Neither T-negative nor
T-positive cells expressed the astrocytic marker glial
edulloblastoma. Four clonal cell lines, BS-1a, BS-1b, BS-1c, and BS-1f,
f cytoplasm and a process-bearing morphology (A through D), were
re similarly derived, although they were morphologically distinct withouse m
egree ofibrillary acidic protein (GFAP) (Figs. 2D and 2H). These
results are consistent with the characteristics of the
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67NOVEL p53 MUTATIONoriginal medulloblastoma tumor tissue obtained from the
JCV T-antigen transgenic mice (Krynska et al., 1999a).
To confirm the presence or absence of T-antigen pro-
tein in the individual cell lines, immunoprecipitation/
Western blot analysis was performed on whole cell ex-
tracts prepared from each line. As shown in Fig. 3A, a
high level of T-antigen protein was detected in cell lines
BS-1B7, BS-1B8, BS-1B13, and BS-1B14 (lanes 1 to 4),
while the other four cell lines showed no detectable
levels of the viral protein (lanes 5 to 8). The individual cell
lines were also examined for the presence of p53. To-
ward this end, immunoprecipitation/Western blot analy-
sis was performed with antibody specific for mouse
wild-type p53 protein (pAb246) or with antibody specific
for mouse mutant p53 protein (pAb240). As shown in Fig.
3B, wild-type p53, but not mutant p53, was detected in
extract prepared from the four T-antigen-positive cell
lines (BS-1B7, BS-1B8, BS-1B13, and BS-1B14), while nei-
ther wild-type nor mutant p53 was detectable in the four
T-antigen-negative cell lines (BS-1a, BS-1b, BS-1c, and
BS-1f).
Next, we utilized immunoprecipitation/Western blot
analysis to determine whether the p53 in the T-antigen-
FIG. 2. Immunohistochemical evaluation of clonal cell lines. Imm
mmunostaining of the cell lines revealed the presence of JCV T-antige
or neuronal cellular marker neurofilament (B and F) and synaptophysi
s shown (D and H).positive cell lines could be found in complex with JCV
T-antigen. Immunoprecipitation was first performed withT-antigen, followed by Western blot analysis with anti-
bodies specific for either p53 or T-antigen. As shown in
Fig. 4A, following immunoprecipitation with antibody to
T-antigen, JCV T-antigen and p53 were detected by West-
ern blot analysis in extract prepared from cell lines BS-
1B13 and BS-1B14, while neither protein was detectable
in extract prepared from the T-antigen-negative cell lines
BS-1c and BS-1f (compare lanes 1 and 3 with lanes 5 and
7). In addition, the reciprocal experiment of immunopre-
cipitation with antibody to p53 followed by Western blot-
ting to detect both T-antigen and p53 revealed a similar
pattern (compare lanes 2 and 4 with lanes 6 and 8).
These results demonstrate that p53 and T-antigen can be
found in complex with each other in extract prepared
from JCV T-antigen-positive cell lines.
Next, sequential immunoprecipitations followed by
Western blot analysis were performed to determine the
relative level of the interaction observed between
T-antigen and p53. First, antibody to p53 was utilized to
pull down the p53:T-antigen complex. This was followed
by Western blot analysis of the immunocomplex using
anti-T-antigen antibody to assess the total amount of
T-antigen bound to p53. To assess the total amount of
ining of BS-1a (A through D) and BS-1B7 (E through H) is shown.
e nuclei of BS-1B7 (B) and its absence in BS-1a (A). Positive staining
d G) is depicted. Negative immunoreactivity for the glial marker GFAPunosta
n in thT-antigen in the extract, immunoprecipitation using anti-
T-antigen was performed in parallel. As shown in Fig. 4B,
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68 KRYNSKA ET AL.immunoprecipitation with antibody to T-antigen revealed
a more intense band than that seen with anti-p53, sug-
gesting that p53 may not be bound to the entire pool of
T-antigen (compare lanes 1 and 2). Following immuno-
precipitation with antibody to T-antigen, the depleted
extract was utilized for a second round of immunopre-
cipitation with antibody to T-antigen. As shown in lane 4,
the primary immunoprecipitation was able to precipitate
T-antigen to near completion. Similarly, immunoprecipi-
tation was performed with antibody to p53, followed by a
secondary precipitation with antibody to T-antigen. As
shown in lane 5, T-antigen in excess of that bound to p53
can be detected in extract prepared from one of the
T-antigen-positive cell lines, while no T-antigen is de-
tected in the reciprocal experiment (lane 6). Of note,
sequential immunoprecipitations with antibody to p53
revealed no cross-reactivity (lane 3). Thus, these results
FIG. 3. Immunoprecipitation/Western blot analysis demonstrates the
resence of T-antigen and wild-type p53 in T-antigen-positive cell lines.
A) Immunoprecipitation/Western blot analysis with antibody to T-anti-
en illustrates the presence of JCV T-antigen in cell lines BS-1B7,
S-1B8, BS-1B13, and BS-1B14 (lanes 1–4) and its absence in cell lines
S-1a, BS-1b, BS-1c, and BS-1f (lanes 5–8). Lane 9 shows the expres-
ion of JCV T-antigen in the positive control hamster glial cells, HJC-15,
roducing JCV T-antigen. (B) Immunoprecipitation with antibodies spe-
ific for either wild-type p53 (pAb246) or mutant p53 (pAb240) revealed
he detection of wild-type p53 in the four T-antigen-positive cell lines
lanes 1–4), but not in the T-antigen-negative cell lines (lanes 5–8). In
ane 9, preimmune serum was used as a control for the detection of p53
n the T-antigen-negative cell line BS-1a. *The positions of immuno-
lobulin heavy chain (A).demonstrate the presence of excess T-antigen, which is
not associated with p53 in T-antigen-positive cell lines.As JCV T-antigen has previously been shown to be
able to interact with the retinoblastoma gene product
pRb (Dyson et al., 1990), extracts from T-antigen-positive
and -negative cell lines were utilized to examine the
FIG. 4. Association of T-antigen with tumor suppressor proteins p53
and pRb in extract prepared from medulloblastoma cell lines. (A)
Immunoprecipitation performed with either antibody to T-antigen or p53
as shown above each lane followed by Western blot analysis using
anti-T-antigen or anti-p53 antibodies. Top and bottom panels, respec-
tively, indicate coprecipitation of T-antigen and p53 in extract from
T-antigen-positive tumor cell lines (lanes 1 through 4), but not in extract
from T-antigen-negative cell lines (lanes 5 through 8). (B) Sequential
immunoprecipitations using antibody to either p53 or T-antigen as
shown above each lane demonstrate the presence of excess T-antigen
not bound to p53 (lane 5). (C) Immunoprecipitation of T-antigen, p53,
and pRb with antibody to these proteins showing the presence of
T-antigen and its association with p53 and pRb in T-antigen-positive
cells (lanes 1 to 3), but not in T-antigen-negative cells (lanes 4 to 6).
Lane 7 represents expression of JCV T-antigen in the positive control,
JCV T-antigen-producing hamster glial cells (HJC-15).
R and s
69NOVEL p53 MUTATIONpossible interaction of T-antigen and pRb. As shown in
Fig. 4C, the total amount of T-antigen protein was de-
tected by immunoprecipitation/Western blot analysis in
two of the T-antigen-positive cell lines, BS-1B13 and
BS-1B14, but not in the T-antigen-negative cell lines,
BS-1c and BS-1f (compare lanes 1 with lanes 4). Like-
wise, the amount of T-antigen, which is in complex with
p53, is precipitated with antibody to p53 (lanes 2). Inter-
estingly, T-antigen was also detected, although at signif-
icantly lower levels, when extract from T-antigen-positive
cells was immunoprecipitated with antibody to pRb
(lanes 3). Detection of a band corresponding to T-antigen
with anti-pRb more faint than that obtained with anti-p53
suggested that JCV T-antigen may have a greater binding
affinity to p53 than pRb in mouse medulloblastoma cells.
As expected, no T-antigen was detected in extract pre-
pared from T-antigen-negative cell lines (compare lanes
3 with lanes 6).
To further investigate the expression of p53 in the
mouse medulloblastoma cell lines, Northern blot analy-
sis was performed utilizing total RNA prepared from the
eight cell lines. As shown in Fig. 5A, a transcript corre-
sponding to the wild-type p53 was detected in the
T-antigen-positive cell lines, BS-1B7, BS-1B8, BS-1B13,
FIG. 5. Northern blot and sequence analyses of the p53 genome in m
from T-antigen-positive (lanes 1 to 4) and T-antigen-negative (lanes 5 to
shows the position of wild-type p53 and the arrowhead points to the
bromide-stained gel (D) demonstrate the integrity of the RNA. (C) RT–PC
a deletion of amino acids 35 to 123 in all four cell lines.and BS-1B14 (lanes 1 to 4, shown by an arrow). Interest-
ingly, a smaller transcript was detected in the T-antigen-negative clones, BS-1a, BS-1b, BS-1c, and BS-1f (lanes 5
to 8, shown by an arrowhead). No variation in the size of
the control GAPDH transcript among these cell lines was
detected (Fig. 5B). To determine whether the smaller
transcript was related to p53, RT–PCR amplification was
performed on mRNA isolated from the T-antigen-negative
cell lines. Sequence analysis of the entire PCR product
spanning the smaller transcript revealed that the four
T-antigen-negative cell lines each contained a p53 tran-
script with a specific deletion that removes amino acid
sequences between 35 and 123 (Fig. 5C). A similar mu-
tation was observed in cell cultures derived from tumors
obtained from other animals (data not shown). These
observations indicate that the genetic alteration seen in
p53 may be frequent in the mouse medulloblastoma and
is not restricted to a single animal. Interestingly, inspec-
tion of the DNA sequence from the mutant p53 cDNA
revealed that this change, which removes the entire exon
4, can create an in-frame smaller p53 species. Interest-
ingly, this region is located near the T-antigen binding
site. These observations indicate that while in T-antigen-
producing cells wild-type p53 is present and in associ-
ation with T-antigen, a specific deletion in p53 in
T-antigen-negative cells results in expression of mutant
lastoma cell lines. (A) Northern blot analysis for p53 on RNA prepared
ls. Radiolabeled mouse p53 cDNA was utilized as a probe. The arrow
nt p53 transcript. Control blot probed with GAPDH (B) and ethidium
equence analyses of the p53 gene in T-antigen negative cells revealededullob
8) cel
mutavariants of p53.
Next, to evaluate the tumorigenecity of the eight cell
o
N
a
-antige
70 KRYNSKA ET AL.lines, 5 3 106 cells from each cell line were subcutane-
FIG. 6. Tumorigenicity of mouse medulloblastoma cell lines in vivo. (
each flank of a Nude mouse and after 2 months tumors were detected a
tumor dissected from the Nude mouse. (C) Immunohistochemical sta
presence of T-antigen in nuclei of the tumor cells. (D and E) H & E and T
in the Nude mouse flank.usly inoculated into the flanks of immunocompromised
ude mice. Interestingly, the T-antigen-positive cell lines
m
tll produced large tumors at the injection sites within 2
T-antigen-positive cell line BS-1B13 was subcutaneously injected into
jection sites. (B) Hematoxylin and eosin (H & E) staining of the BS-1B13
f the BS-1B13-induced tumor with anti-T-antigen antibody shows the
n staining, respectively, of small tumors derived from injection of BS-1aA) The
t the in
ining oonths of inoculation. Figure 6A illustrates results from
he transplantation of BS-1B13 into Nude mice 8 weeks
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71NOVEL p53 MUTATIONafter inoculation. Only one of the T-antigen-negative cell
lines, BS-1a, developed a small, yet palpable tumor 2
months after injection (data not shown). Histological
evaluation of the tumors generated by BS-1B13 and
BS-1a revealed characteristics similar to those of the
native medulloblastomas in the transgenic mice, includ-
ing small blue cells with scant cytoplasm (Figs. 6B and
6D, respectively). Some evidence of neuroblastic differ-
entiation was also noted in BS-1B13 (Fig. 6B). Immuno-
histochemical analysis of the tumors revealed the pres-
ence of JCV T-antigen in the nucleus of the majority of
tumor cells generated by T-antigen-positive cell line, BS-
1B13. T-antigen was not detectable in the small palpable
tumor derived from the T-antigen-negative cell line,
BS-1a (compare Fig. 6C with 6E).
DISCUSSION
The paradigm of polyomavirus-induced malignancy
provides a unique model system for dissecting pathways
involved in the formation and progression of tumors. The
viral early protein, T-antigen, has the ability to interact
with and functionally inactivate two classes of tumor
suppressors, i.e., p53 and pRb, both of which are essen-
tial for cell growth and differentiation. Further, the role of
p53 in genome stability has recently been well docu-
mented (Rotter et al., 1994). This is an important notion,
as inactivation of these tumor suppressors caused by
genetic variations in their genomes is a common event in
the genesis of several human tumors. In the context of
several recent studies pointing to the association of
polyomavirus and human malignancy, we became par-
ticularly interested in the role of the human polyomavirus
JCV in tumorigenesis. Seroepidemiological studies have
shown that infection with JCV occurs in a vast majority of
the human population (Walker and Padgett, 1983). Cell
biological and biochemical studies have demonstrated
that the virus possesses an oncogenic early protein,
T-antigen, that can associate with several tumor sup-
pressors (Dyson et al., 1990; Krynska et al., 1997). In this
espect, the development of medulloblastoma in trans-
enic mice expressing JCV T-antigen may offer an excel-
ent model system for understanding the changes in the
egulatory factors during the path to tumorigenesis. The
oexistence of T-antigen-positive and T-antigen-negative
ell populations in the tumor tissue and the derivation of
hese cells from the tumors are particularly interesting
bservations. Sequencing of the viral genome in the
-antigen-negative cells revealed no sequence varia-
ions in the transgenes, which may contribute to the lack
f T-antigen expression in these cells (data not shown).
hus, one may speculate that silencing of the JCV pro-
oter in the T-antigen-negative cells may be caused by
he presence of transcription suppressors and/or the
bsence of transcription activation in these cells. Our
uture studies are aimed at unraveling the mechanisms
p
tinvolved in the modulation of JCV promoter activity in
these tumor cells. The lack of T-antigen expression in the
tumor cells, however, shows little, if any, effect on prolif-
eration of the cells in culture. Furthermore, results from
trypan blue exclusion assay of the T-antigen-positive and
T-antigen-negative cells revealed no drastic differences
in the growth rates of the cells (Krynska, unpublished
observations). However, results from Nude mouse stud-
ies revealed that unlike T-antigen-negative cells, the T-
antigen-positive cells can induce large tumors in the
flanks of injected animals. This is an interesting obser-
vation in light of earlier studies on a rat model that was
developed by retrovirus-transduced SV40 T-antigen
(Salewski et al., 1999). In that setting, it was reported that
the lack of T-antigen expression resulted in a rapidly
growing malignant tumor. While the discrepancy be-
tween these two observations remains to be investi-
gated, one may speculate that differences in the animal
models, i.e., transgenic mice vs retrovirally transduced
rats, and the variations in the biological activity of
T-antigen from JCV and SV40 may contribute to this
inconsistency. Nevertheless, in both studies, p53 was
found to be present in the wild-type form and in associ-
ation with T-antigen in T-antigen-producing cells, while
p53 was mutated in T-antigen-negative cells.
Our results have shown the occurrence of a novel
mutation in the p53 gene which removes a large portion
within the N-terminus of p53. This region overlaps with
exon 4 of murine p53 and its deletion leaves the remain-
ing p53 sequence in-frame. Curiously, results from West-
ern blot analysis failed to detect this mutant p53 protein,
suggesting that similar to the full-length wild-type p53,
this variant of p53 is extremely unstable and has a short
half-life. Detection of a mutant p53 cDNA sequence that
lacks exon 4 suggests that perhaps changes in the
nucleotide sequence of the genome of p53 altered the
splicing signals required for appropriate splicing of p53
and caused exon 4 deletion. A detailed genetic analysis
of the p53 genome is required to further determine the
mechanism for the appearance of a p53 deletion in
T-antigen-negative cells. Perhaps it should be noted that
earlier studies from several laboratories reported alter-
native splicing of p53 (Flaman et al., 1996; Kulesz-Martin
t al., 1994; Will et al., 1995). The previously reported
lternative that affects the C-terminal of this protein is an
nsertional mutation and is distinct from the deletion
utation that we observed in the N-terminal of this gene
n mouse medulloblastoma. As mentioned earlier, re-
oval of exon 4, which is located in close proximity to the
-antigen binding site, may affect proper folding of the
rotein and its binding to T-antigen. Therefore, according
o one model, a mutation in the p53 genome may result
n an alternative pattern of splicing leading to the gen-
ration of a p53 variant with no exon 4 which encom-
asses the T-antigen binding site. This allows dissocia-
ion of T-antigen from the p53 mutant in the tumor cells.
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72 KRYNSKA ET AL.The free T-antigen may, in turn, through a known nega-
tive autoregulatory pathway, suppress expression of its
own promoter. As such, the result will be proliferation of
T-antigen-negative tumor cells with a deletion mutation
in p53. The region of p53 that is deleted in the T-antigen-
negative cells, i.e., residues 35–123, possesses several
important functional features. For example, the residues
between 63 and 97 that are proline-rich have similarity to
SH3-binding protein and are required for p53-mediated
apoptosis in some experimental systems (Sakamuro et
al., 1997). More interestingly, this region plays a role in
uppressing tumor cell growth (Walker and Levine, 1996)
nd is a target for papillomavirus E6-protein-induced p53
egradation (Li and Coffino, 1996). While the importance
f this novel p53 mutant in the tumorigenecity of medul-
oblastoma in experimental animals remains to be inves-
igated, one may speculate that such a large deletion in
he N-terminal of p53 may functionally inactivate p53 and
esult in rapid cell growth in these tumor cells. Future
tudies are aimed at investigating the biological activity
f mutant p53 utilizing p53 null cells and at determining
hether expression of p53 with a deletion in exon 4
ffects growth property of these cells. Further, it is inter-
sting to determine whether dimerization of mutant p53
ith wild type affects the activity of wild-type p53. Clini-
ally, it is of particular interest to determine the occur-
ence of the p53 N-terminal deletion in human medullo-
lastomas.
MATERIALS AND METHODS
Generation of medulloblastoma cell lines
The cell lines were established from a tumor dissected
from a transgenic mouse brain harboring JCV T-antigen
(Krynska et al., 1999a). Tissue specimens were washed
several times with cold phosphate-buffered saline and
cut into 0.5- to 1.0-mm segments. Sections were then
cultured in DMEM containing 10% FCS and antibiotics.
Adherent cells were subcultured at confluence and indi-
vidual medulloblastoma cell lines were established us-
ing a limited dilution method.
Histology and immunohistochemistry
Cultured cells were plated onto poly-L-lysine-coated
glass chamber slides (Nunc) for light microscopy and
immunocytochemistry. Immunohistochemistry was per-
formed on formalin-fixed cells or paraffin-embedded tu-
mor tissue using the avidin–biotin–peroxidase complex
system according to the manufacturer’s instructions and
as described in detail previously (Vectastain Elite ABC
peroxidase kit, Vector Laboratories; Krynska et al.,
1999b). Antibodies utilized for immunostaining included
pAb416 to recognize JCV T-antigen (Oncogene Science),
6F2 for glial fibrillary acidic protein (Dako), SY38 for
synaptophysin (Roche), NF100 for neurofilament (Stern-
cberger Monoclonals, Inc.), and a rabbit polyclonal anti-
body to recognize mouse p53 (Chemicon). Hematoxylin
and eosin staining was performed on paraffin-embedded
samples for routine histological analysis.
Immunoprecipitation/Western blot analysis
Immunoprecipitation/Western blots were performed
using extract made from either T-antigen-positive or
T-antigen-negative cells in TNN buffer containing 100
mM Tris (pH 8.0), 100 mM NaCl, and 0.5% NP-40 plus
protease inhibitors (2 mg/ml aprotinin, 10 mg/ml leupep-
in, 10 mg/ml pepstatin, 100 mg/ml PMSF, 100 mg/ml
TPCK). Positive control extracts were made from the
HJC-15 cell line (Raj et al., 1995). Fifty to one hundred
micrograms of total protein in 150–300 ml of TNN buffer
as incubated overnight with 5 ml of antibody. The im-
munocomplexes were analyzed by SDS–PAGE followed
by Western blot using specific antibodies as indicated in
the text. For detection of p53, pAb421, which recognizes
both wild-type and mutant p53, pAb240, which detects
only mutant p53, or pAb246, which only interacts with
wild-type p53, was utilized. For detection of T-antigen,
SV40 T-antigen monoclonal antibody pAb416 (Oncogene
Science), which recognizes JCV T-antigen, was utilized.
Since the immunoglobulin heavy chain of the primary
antibody used for immunoprecipitation may obscure de-
tection of the p53 protein, protein A–Sepharose conju-
gated to alkaline phosphatase (Pierce) was utilized as a
secondary antibody, as it recognizes only native IgG
complexes, and not the denatured heavy chain. All bands
were visualized by chemiluminescence using CDP-STAR
(NEN–DuPont) according to the manufacturer’s protocol.
RNA and DNA extraction from medulloblastoma cell
lines
Total RNA was isolated from medulloblastoma cell
lines by acid–guanidinium, thiocyanate–phenol–chloro-
form extraction as described previously (Chomczynski
and Sacchi, 1987). Genomic DNA was prepared from
medulloblastoma cells by using the Puregene DNA Iso-
lation Kit (GENTRA) according to the manufacturer’s in-
structions.
RT and PCR amplification of p53 cDNA for
sequencing
One microgram of DNase-treated RNA was incubated
with 40 U of recombinant Moloney murine leukemia virus
reverse transcriptase (RT) (Roche) at 45°C for 30 min in
a 20-ml reaction in the presence of 40 U of RNasin, 250
mM of each dNTP, and 0.5 mM primer R3 (59-GGCCAG-
AACCACTACTCAG) to generate the cDNA. The sam-
les were then heated to 95°C for 5 min to inactivate the
everse transcriptase. Five microliters of the resulting
DNA was used for PCR in a total volume of 50 ml in the
presence of 250 mM MgCl2, 200 mM of each dNTP, 0.5
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The primer L4 (59-AGTTCATTGGGACCATCCTG-39) was
used for second-strand synthesis. After initial denatur-
ation for 5 min at 94°C, PCR was performed for 25 cycles
of 95°C (15 s), 58°C (30 s), and 72°C (45 s) with a final
extension of 7 min at 72°C. The resulting RT–PCR prod-
ucts were excised from preparatory agarose gels stained
with ethidium bromide, and DNA was purified using the
QIAquick PCR Purification Kit according to the manufac-
turer’s instructions (Qiagen). After extraction, DNA was
sequenced by automated fluorescent DNA cycle se-
quencing using the Applied Biosystems Prism 377 DNA
Sequencer-XL. The following primers were used for se-
quencing of the p53 gene: L4 (59-AGTTCATTGGGAC-
CATCCTG-39); L2 (59-CGGGTGGAAGGAAATTTGTA-39);
and L5 (59-AGAGACCGCCGTACAGAAGA-39).
Northern blot analysis of p53
Approximately 10 mg of total RNA was size fraction-
ted on formaldehyde/agarose gel, stained with
thidium bromide, and then transferred to nylon mem-
rane (Hybond-N, Amersham). Prehybridization was
erformed in Ultrasensitive Hybridization Solution–
LTRAhyb (Ambion) for 1 h at 65°C followed by hy-
ridization in the same solution containing radiola-
eled full-length mouse p53 cDNA overnight at 42°C.
ollowing hybridization, the nylon membrane was
ashed with 23 SSC and 0.1% SDS followed by 0.13
SC and 0.1% SDS at 42°C, air-dried, and exposed to
-ray film overnight at 270°C.
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